<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789762</url>
  </required_header>
  <id_info>
    <org_study_id>2012-P001</org_study_id>
    <nct_id>NCT01789762</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process</brief_title>
  <acronym>EFFIPAP</acronym>
  <official_title>Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Investigation Clinique - Hospital of Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Etablissement Français du Sang</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: French Data Protection Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentre, double-blind, randomized therapeutic trial.

      The primary objective of this study is to evaluate non-inferiority with regard to prevention
      and control of haemorrhage:

        -  of platelet concentrates treated by pathogen reduction(Intercept  amotosalen and UVA
           procedure)

        -  compared with the usual platelet concentrates (in additive solution intersol),
           reference arm, and

        -  compared with platelet concentrates re-suspended in autologous plasma (historic arm)
           These three products are available and authorised by ANSM (formerly AFSSAPS).

      The secondary objectives is to evaluate the transfusion needs, transfusion outcomes and
      safety and the decreased frequency of grade 2 or higher side effects related to transfusion
      allergy to platelets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an unresolved difficulty in the evaluation of haemorrhagic symptoms in
      thrombocytopenia due to the very nature of the scale, which is the international standard at
      this time (WHO scale). This scale is based on the level of blood loss and is applicable to
      any haemostasis disorder. We will keep it as the standard but have decided to be
      particularly rigorous in the data collection and will perform daily haemorrhagic assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of grade 2 or higher (WHO) haemorrhagic episodes</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency incidence of haemorrhagic episodes  (grade 1 and higher)</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious grade 3-4 haemorrhagic episodes</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of minor grade 1 haemorrhagic episodes</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion outcome in platelets (CCI) at 24 hours</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transfusions of platelet concentrates and red blood cells</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion intervals</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (transfusion side effects) grade 2 or higher</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-platelet antibodies (Anti-HLA, anti-HPA)</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of platelet transfusions refractiveness</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of a new haemorrhagic evaluation: EFS scale</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation  in hematocrit and hemoglobin levels</measure>
    <time_frame>During 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">810</enrollment>
  <condition>Aplasia With Expected Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Historical control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients transfused with platelet concentrates re-suspended in autologous plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients transfused with platelets prepared in additive solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients transfused with platelets treated by pathogen reduction process</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous plasma</intervention_name>
    <description>Transfusions of platelet concentrates re-suspended in autologous plasma</description>
    <arm_group_label>Historical control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Additive solution</intervention_name>
    <description>Transfusions of platelets prepared in additive solution (Intersol)</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pathogen reduction process</intervention_name>
    <description>Patients transfused with platelets treated by pathogen reduction process</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or older

          -  Patient hospitalised for bone marrow aplasia, with expected stay of over 10 days and
             in principle requiring platelet transfusion support (at least twice).

          -  Signed informed consent

          -  Patients with DIC can be included; they will undergo a separate analysis.

          -  A negative pregnancy test is necessary before inclusion in all women of childbearing
             age

        Exclusion Criteria:

          -  Patient included in this trial previously during a prior aplasia episode.

          -  Patient requiring curative anticoagulant treatment at the time of inclusion (vitamin
             K antagonists, heparin (LMWH and NFH), anti-IIa and Xa at curative doses for
             treatment or prophylaxis of arterial or venous thromboembolic disease (TED) or as
             part of the treatment for cardiac valvulopathy and complications of atrial
             fibrillation).

          -  Thrombocytopenia due to increased destruction

          -  Patient requires washed platelet concentrates (i.e., with residual plasma less than
             that remaining during the addition of an additive solution) due to previous
             intolerance to platelets (cf IgA deficiency, history of major allergic reaction)

          -  Patient requiring products &quot;CMV negative &quot; (previously included in a protocol
             transfusion CMV negative)

          -  Patients with platelet transfusion refractoriness during a previous period of
             cytopenia, including patient with platelet refractoriness related to an anti-HLA
             alloimmunization (thus, patient already known as requiring compatible platelets HLA)

          -  Patient who requires compatible HLA platelets due to a refractory state relative to
             anti-HLA alloimmunization

          -  Patient presenting a platelet transfusion refractoriness at the time of previous
             aplasia.

          -  Protected adults and persons deprived of liberty
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Tiberghien, MD, PhD</last_name>
    <phone>+33 (0) 1 55 93 95 90</phone>
    <email>pierre.tiberghien@efs.sante.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederic Garban, MD, PhD</last_name>
    <phone>+33 (0) 4 76 42 43 44</phone>
    <email>frederic.garban@efs.sante.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Deconinck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Le Niger, MD</last_name>
      <email>catherine.leniger@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques-Olivier Bay, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor - APHP</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine Cordonnier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis Caillot, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Garban, MD, PhD</last_name>
      <phone>+33 (0) 4 76 42 43 44</phone>
      <email>frederic.garban@efs.sante.fr</email>
    </contact>
    <investigator>
      <last_name>Frederic Garban, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Ladaique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Lapusan, MD</last_name>
      <email>simona.lapusan@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hélène Labussière, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stanislas Nimubona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>St Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Mounier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet transfusions</keyword>
  <keyword>Pathogen reduction</keyword>
  <keyword>Haemorrhagic episodes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
